Patients with myeloproliferative neoplasms (MPN) are at risk of splanchnic vein thrombosis (SVT). Previous studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but they are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of patients with MPN-SVT from the international GASTRO-MPN consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of whom 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/transjugular intrahepatic portosystemic shunt thrombosis, and 138 (18%) had a thrombosis recurrence outside the splanchnic bed (74% were venous). In addition, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, previous thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.89; P = .01). This was driven by a lower risk of SVT extension/recurrence (HR, 0.62; 95% CI, 0.42-0.90; P = .01) but not by extra-splanchnic thrombosis recurrence (HR, 0.97; 95% CI, 0.72-1.30; P = .82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n = 275), cytoreductive therapy was associated with an HR of 0.65 (95% CI, 0.40-1.07; P = .09) for recurrent thrombosis. These data support the use of cytoreductive therapy for patients with MPN-SVT to prevent recurrent thrombosis, particularly SVT extension/recurrence.